What is claimed is:

1. Use of an FGFR3 inhibitor in combination with a therapeutically effective amount of a PD1 inhibitor in the manufacture of a medicament for treating a solid tumor.

2. The use of claim 1, wherein the FGFR3 inhibitor is an antagonistic FGFR3 antibody.

3. The use of claim 2, wherein the antagonistic FGFR3 antibody comprises CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO:1, CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO:2, and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO:3.

4. The use of claim 3, wherein the antagonistic FGFR3 antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:7.

5. The use of claim 2, wherein the antagonistic FGFR3 antibody comprises CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO:4, CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO:5, and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:6.

6. The use of claim 5, wherein the antagonistic FGFR3 antibody comprises a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:8.

7. The use of claim 1, wherein the PD1 inhibitor is an antagonistic PD1 antibody.

8. The use of claim 7, wherein the antagonistic PD1 antibody is selected from the group consisting of nivolumab, pembrolizumab, CT-011, MEDI-0680, and RMP1-14.

9. The use of claim 1, wherein the PD1 inhibitor is an antagonistic PD1 ligand antibody.

10. The use of claim 9, wherein the antagonistic PD1 ligand antibody is selected from the group consisting of MEDI-4736, RG7446, BMS-936559, MSB0010718C, and MPDL3280A.

11. A pharmaceutical composition comprising an FGFR3 inhibitor and a PD1 inhibitor.

12. The composition of claim 11, further comprising a pharmaceutically acceptable carrier.

13. The composition of claim 11, wherein the FGFR3 inhibitor is an antagonistic FGFR3 antibody.

14. The composition of claim 13, wherein the antagonistic FGFR3 antibody comprises CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO:1, CDR-H2

comprising the amino acid sequence set forth in SEQ ID NO:2, and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO:3.

15. The composition of claim 14, wherein the antagonistic FGFR3 antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:7.

16. The composition of claim 13, wherein the antagonistic FGFR3 antibody comprises CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO:4, CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO:5, and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:6.

17. The composition of claim 16, wherein the antagonistic FGFR3 antibody comprises a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:8.

18. The composition of claim 11, wherein the PD1 inhibitor is an antagonistic PD1 antibody.

19. The composition of claim 18, wherein the antagonistic PD1 antibody is selected from the group consisting of nivolumab, pembrolizumab, CT-011, MEDI-0680, and RMP1-14.

20. The composition of claim 11, wherein the PD1 inhibitor is an antagonistic PD1 ligand antibody.

21. The composition of claim 20, wherein the antagonistic PD1 ligand antibody is selected from the group consisting of MEDI-4736, RG7446, BMS-936559, MSB0010718C, and MPDL3280A.